Director Gary W. Pace granted 40,565 Cardiff Oncology (CRDF) stock options at $1.59

Rhea-AI Filing Summary

Cardiff Oncology director Gary W. Pace received a new stock option grant. He was awarded options covering 40,565 shares of common stock at an exercise price of $1.59 per share. Following this grant, he holds options over a total of 228,104 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider PACE GARY W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	40,565	$0.00	--

Holdings After Transaction: Stock Options — 228,104 shares (Direct, null)

Footnotes (1)

Key Figures

Option grant size: 40,565 options Exercise price: $1.59 per share Total options after grant: 228,104 options

3 metrics

Option grant size 40,565 options Grant of stock options to director Gary W. Pace

Exercise price $1.59 per share Exercise price for newly granted stock options

Total options after grant 228,104 options Total options held by Gary W. Pace following transaction

Key Terms

Stock Options, Grant, award, or other acquisition, Common Stock, exercise price

4 terms

Stock Options financial

"security_title: "Stock Options""

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: "1.5900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PACE GARY W

(Last) (First) (Middle)

C/O CARDIFF ONCOLOGY, INC.

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.59	06/11/2026		A		40,565		06/11/2027	06/11/2036	Common Stock	40,565	$0	228,104	D

Explanation of Responses:

	/s/ Gary Pace	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cardiff Oncology (CRDF) report for Gary W. Pace?

Cardiff Oncology reported that director Gary W. Pace received a stock option grant covering 40,565 shares of common stock. This is a compensation-related award rather than an open-market purchase or sale of existing shares.

What is the exercise price of Gary W. Pace’s new Cardiff Oncology (CRDF) stock options?

The newly granted stock options to Gary W. Pace have an exercise price of $1.59 per share. This is the price he must pay per share to convert the options into Cardiff Oncology common stock in the future.

How many Cardiff Oncology (CRDF) option shares does Gary W. Pace hold after this grant?

After this grant, Gary W. Pace holds stock options over 228,104 shares of Cardiff Oncology common stock. This total includes the newly granted 40,565 options and reflects his aggregate derivative position reported in this filing.

Was Gary W. Pace’s Cardiff Oncology (CRDF) Form 4 transaction a buy or a sale?

The Form 4 shows an acquisition through a grant, not a market buy or sale. The transaction is coded as a grant or award of 40,565 stock options, with no open-market purchase or disposition involved.

What type of security was involved in Gary W. Pace’s Cardiff Oncology (CRDF) Form 4?

The transaction involved stock options that are exercisable into Cardiff Oncology common stock. These derivative securities give Gary W. Pace the right to acquire 40,565 shares at a fixed exercise price of $1.59 per share in the future.